Community post

Pherecydes Pharma intends to list on the Euronext Growth® Market in Paris, a European equity trading market designed for small to medium-sized firms. Pherecydes Pharma has developed a portfolio of phages against Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and will be pursuing an individualized treatment strategy which includes screening a large number of phages and selecting the efficient ones using a phagogram.